10-Q: Alexandria Reports Q3 Loss Amid Impairments & Market Headwinds

Alexandria Real Estate Equities, Inc. reported a significant net loss for the nine months ended September 30, 2025, driven by substantial real estate impairments and a challenging life science market.

Summary

• Reported a net loss of $348.7 million for the nine months ended September 30, 2025, compared to a net income of $385.2 million in the prior year.
• Diluted Earnings Per Share (EPS) was $(2.09) for the nine months ended September 30, 2025, down from $2.18 in the prior year.
• Total revenues decreased by 2.4% to $2.27 billion for the nine months ended September 30, 2025, though excluding dispositions, revenues would have increased by 3.0%.
• Real estate impairments surged to $485.6 million for the nine months ended September 30, 2025, a significant increase from $36.5 million in the prior year.
• Funds From Operations (FFO) per share, as adjusted, decreased to $6.85 for the nine months ended September 30, 2025, from $7.08 in the prior year.
• Operating occupancy declined to 90.6% as of September 30, 2025, from 94.7% a year prior.
• General and administrative expenses decreased by 34% to $89.0 million for the nine months ended September 30, 2025, due to cost-control initiatives.
• Interest expense increased by 23.7% to $161.0 million for the nine months ended September 30, 2025.
• Completed $340.9 million in dispositions during the nine months ended September 30, 2025, with a full-year target of $1.5 billion.
• Leasing volume for the three months ended September 30, 2025, was 1,171,344 RSF, including a record 16-year build-to-suit lease for 466,598 RSF.
• Rental rate increases on lease renewals and re-leasing of space were 6.1% (cash basis) for the three months ended September 30, 2025, and 6.8% (cash basis) for the nine months ended September 30, 2025.
• The company maintains $4.2 billion in liquidity as of September 30, 2025.
• Net debt and preferred stock to Adjusted EBITDA ratio was 6.1x (annualized for the three months ended September 30, 2025), exceeding the previous target of less than or equal to 5.2x.
• The 2000 Deferred Compensation Plan was amended and restated effective October 1, 2025.

Sentiment

Score: 3

Explanation: The company reported a substantial net loss and increased real estate impairments, coupled with declining occupancy and a downward revision of key financial guidance. While there are positives like G&A cost reductions and significant leasing activity, the overall financial performance and outlook are negatively impacted by macroeconomic headwinds and industry-specific challenges.

Positives

• General and administrative expenses decreased significantly by 34% to $89.0 million for the nine months ended September 30, 2025, due to cost-control and efficiency initiatives.
• Achieved a substantial leasing volume of 1,171,344 RSF during the three months ended September 30, 2025, including the largest life science lease in company history (466,598 RSF, 16-year build-to-suit).
• Rental rate increases on lease renewals and re-leasing of space were 15.2% (GAAP) and 6.1% (cash basis) for the three months ended September 30, 2025, and 13.6% (GAAP) and 6.8% (cash basis) for the nine months ended September 30, 2025.
• Maintained strong liquidity of $4.2 billion as of September 30, 2025, providing flexibility for operational needs and strategic opportunities.
• The company's credit ratings (BBB+ from S&P Global Ratings and Baa1 from Moody's Ratings) rank in the top 15% among publicly traded U.S. REITs.
• 88.6% of total debt is fixed-rate, providing predictability in debt servicing costs.
• The weighted-average remaining term of debt is 11.6 years, the longest among S&P 500 REITs.
• 76% of the total development and redevelopment pipeline RSF is within Megacampus ecosystems, aligning with a high-demand strategy.
• Tenant collections remained consistently high, averaging 99.8% from the beginning of 2021 through September 30, 2025.
• Excluding dispositions, total revenues would have increased by 3.0% for the nine months ended September 30, 2025.
• Approximately half of the $49 million General and Administrative cost reductions expected to be achieved in 2025 are anticipated to continue in 2026.

Negatives

• Reported a net loss of $348.7 million for the nine months ended September 30, 2025, a significant decline from $385.2 million net income in the prior year.
• Diluted EPS decreased to $(2.09) for the nine months ended September 30, 2025, from $2.18 in the prior year.
• Total revenues decreased by 2.4% for the nine months ended September 30, 2025.
• Real estate impairment charges significantly increased to $485.6 million for the nine months ended September 30, 2025, from $36.5 million in the prior year.
• FFO per share, as adjusted, decreased to $6.85 for the nine months ended September 30, 2025, from $7.08 in the prior year.
• Operating occupancy declined to 90.6% as of September 30, 2025, from 94.7% a year prior, and has decreased for four consecutive quarters.
• Same property net operating income (cash basis) decreased by 3.1% for the three months ended September 30, 2025, compared to the three months ended September 30, 2024.
• Net debt and preferred stock to Adjusted EBITDA ratio increased to 6.1x (annualized for the three months ended September 30, 2025), exceeding the previous target of less than or equal to 5.2x.
• Investment income shifted to a loss of $52.5 million for the nine months ended September 30, 2025, from a gain of $14.9 million in the prior year.
• Net cash provided by operating activities decreased by $128.7 million to $1.1 billion for the nine months ended September 30, 2025, primarily due to a ground lease prepayment.
• The company reduced its 2025 guidance for net (loss) income per share and FFO per share (as adjusted), and increased its net debt to Adjusted EBITDA target.
• Expected delays in closing $450 million of dispositions, now anticipated in the first half of 2026.
• The Board of Directors expects to carefully evaluate the 2026 dividend strategy due to potential reductions in FFO per share and net cash provided by operating activities.

Risks

• New competitive supply of laboratory space, including repurposing of office spaces, may exert pressure on rental rates and occupancy, requiring reduced rates or increased concessions.
• Existing operating properties may require additional revenueand non-revenue-enhancing capital investments earlier than expected.
• Elevated supply of new laboratory space, high interest rates, and reduced market liquidity have led to lower property valuations and higher capitalization rates, potentially causing significant additional real estate impairments and challenging asset sales.
• Increased cost and limited availability of capital due to elevated benchmark interest rates may hinder the ability to fund construction projects or lead to costlier debt options.
• Volatility in non-real estate investments due to macroeconomic challenges and a tighter capital environment in the life science industry could lead to lower realized gains and potential impairments.
• Government policy and regulatory disruption, including FDA layoffs (approximately 3,500 employees, 19% of workforce), CDC restructuring, NIH grant cuts (40% proposed budget reduction), and drug pricing regulations (Most-Favored Nation Executive Order, Medicaid funding cuts), could negatively impact tenants and demand for life science real estate.
• Rapid expansion of China's biotechnology sector, fueled by state subsidies and regulatory reform, could negatively impact demand for U.S. laboratory space and shift R&D activities abroad.
• Tariff escalation, trade disruption, and financial market instability (e.g., 100% tariff on imported branded/patented drugs) could restrict access to capital, raise construction costs, and adversely affect tenant operations.
• A prolonged or repeated U.S. government shutdown could adversely affect tenants dependent on federal funding, contracts, or regulatory actions, potentially leading to delays in drug approvals, grant applications, and increased risk of lease defaults.
• The life science industry faces prolonged structural and cyclical challenges, including contraction in venture capital funding for early-stage companies, leading to reduced company formation and tenant demand.
• The company's ability to raise capital to fund future development projects may be impacted if capital markets perceive the life science sector as structurally challenged, increasing the cost of capital or constraining access to financing.
• Potential for additional impairments ranging from $0 to $685 million during the fourth quarter of 2025 if certain assets meet held-for-sale criteria.
• Expected downtime of 6 to 24 months on a weighted-average basis for 1.2 million RSF of key lease expirations in the first half of 2026.
• Future pipeline projects with $4.2 billion average real estate basis capitalized for pre-construction activities may be paused or disposed of, leading to expensing of related costs.

Future Outlook

The company anticipates continued challenges in the life science sector due to slower demand and increased supply, potentially impacting future occupancy and requiring a reevaluation of the 2026 dividend strategy. It expects to deliver $111 million of incremental annual net operating income from development projects by the fourth quarter of 2026, with 80% leased/negotiating. Construction spending for 2026 is projected to be similar or slightly higher than the $1.75 billion midpoint for 2025. The company plans to end its large-scale non-core asset sales program in 2026 or early 2027. Future pipeline projects with $4.2 billion in capitalized real estate basis will be evaluated for continuation, pausing, or disposition based on market conditions and leasing demand, potentially leading to expensing of related costs.

Management Comments

• Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus ecosystems in AAA life science innovation cluster locations.
• We believe in the utmost professionalism, humility, and teamwork.
• Our Megacampus ecosystems are designed for optionality and scalability, offering our tenants a clear path to address their growth requirements.
• We expect to fund a significant portion of our capital requirements for the year ending December 31, 2025, through dispositions of non-core assets, land, partial interest sales, and sales to owner/users.
• Given that some of these cost savings are expected to be temporary in nature, we anticipate approximately half of the cost reductions expected to be achieved in 2025 will continue in 2026.
• Our strategic focus is on prioritizing the completion of our projects under construction that are highly leased.
• We expect a significant source of funding from the sale of non-core assets in 2026. We anticipate an end to our large-scale non-core asset sales program in 2026 or early 2027.
• We expect our Board of Directors to carefully evaluate our 2026 dividend strategy.

Industry Context

The life science industry is facing a prolonged period of structural and cyclical challenges, including a contraction in venture capital funding for early-stage companies, leading to reduced company formation and tenant demand. There's an increased competitive supply of laboratory space, partly due to office-to-lab conversions, heightening pressure on rental rates and occupancy. Government policy shifts, such as FDA layoffs, NIH grant cuts, and drug pricing regulations, are introducing significant volatility and uncertainty, potentially slowing R&D, delaying approvals, and impacting funding. The rapid expansion of China's biotechnology sector also poses a risk of shifting R&D activities abroad. Macroeconomic factors like elevated interest rates and trade tariffs are increasing capital costs, disrupting supply chains, and impacting property valuations. However, there's an observed improvement in the broader office market, particularly from the technology sector (AI), which may absorb some supply previously targeted for life science use, potentially alleviating oversupply in the life science sector.

Comparison to Industry Standards

• General and administrative expenses for the trailing twelve months ended September 30, 2025, were 5.7% of net operating income, which is approximately half the average of other S&P 500 REITs.
• The weighted-average remaining term of debt is 11.6 years, which is the longest among S&P 500 REITs.
• Credit ratings (BBB+ from S&P Global Ratings and Baa1 from Moody's Ratings) rank in the top 15% among all publicly traded U.S. REITs.
• 17 of the top 20 pharma R&D spenders (for 2023) are Alexandria tenants, indicating a strong tenant base among industry leaders.
• The company highlights its 'Megacampus ecosystems' as a defense against competitive supply, contrasting them with 'isolated facilities that provide operational space but lack the scale and strategic design'.

Corporate Governance

Legal Proceedings

• ARE-East River Science Park, LLC filed a lawsuit on August 6, 2024, against New York City Health + Hospitals Corporation (H+H) and New York City Economic Development Corporation (EDC) for fraud in the inducement and breach of contract.
• The lawsuit alleges misrepresentations and concealment of material facts regarding a floodwall that H+H and EDC require to be integrated into the development of the Option Parcel at the Alexandria Center for Life Science New York City campus.
• The misconduct has prevented the commencement of development of the Option Parcel, where $175.7 million in pre-construction costs have been invested.
• The closing date for the option and construction commencement for the third tower are indeterminate.
• ARE-East River Science Park, LLC is seeking significant damages and equitable relief, with potential losses ranging from zero to the full $175.7 million investment.

Related Party Transactions

• In September 2025, the company completed an exchange of partial interests with a joint venture partner, selling its 50% controlling interest in Pacific Technology Park and acquiring the partner's 70% noncontrolling interest in 199 East Blaine Street.
• In March 2025, the company redeemed partners' entire noncontrolling interests in three real estate joint ventures in the Greater Boston market, with a book value aggregating $10.4 million, recognizing $7.0 million of consideration in excess of the book value in additional paid-in capital.
• In July 2025, the company amended the agreement for its consolidated real estate joint venture at 99 Coolidge Avenue, adjusting the partner's noncontrolling interest and converting it into a $48.7 million redeemable noncontrolling interest that accrues a fixed 4.05% annual preferred return and includes a put option beginning January 2026.

Stakeholder Impact

• Shareholders: Negative impact due to significant net loss, declining EPS, reduced FFO, increased leverage, and potential reevaluation of dividend strategy. Potential dilution from future equity offerings.
• Employees: Cost-control and efficiency initiatives include headcount reduction and restructuring of compensation plans.
• Tenants: Facing challenges from new competitive supply, government policy changes (FDA, NIH, drug pricing), and tariffs, potentially leading to reduced demand, downsizing, or lease defaults. However, the Megacampus strategy aims to support tenant growth and talent retention.
• Creditors: Increased net debt to Adjusted EBITDA ratio and reduced fixed-charge coverage ratio indicate higher leverage, though credit ratings remain strong.
• Joint Venture Partners: Impacted by changes in joint venture agreements, such as the 99 Coolidge Avenue amendment and the Pacific Technology Park/199 East Blaine Street exchange.

Next Steps

• Introduce 2026 guidance on December 3, 2025, at Investor Day.
• Complete pending dispositions aggregating $1.0 billion, expected to close in late Q4 2025.
• Evaluate future pipeline projects (with $4.2 billion average real estate basis capitalized) on an asset-by-asset basis to decide whether to proceed with construction, pause investments, or consider dispositions.
• The Board of Directors will carefully evaluate the 2026 dividend strategy.
• Continue to monitor macroeconomic trends, trade relations, and government policies for potential impacts on business and tenants.
• Continue to implement mitigating strategies against industry headwinds, including deepening relationships with venture capital firms, expanding proprietary products, and exploring strategic partnerships.

Key Dates

Recommendation

The company reported a significant net loss, a substantial increase in real estate impairments, and a decline in key performance metrics like FFO per share and operating occupancy. The revised 2025 guidance reflects a worsening outlook, with increased leverage targets and a potential reevaluation of the dividend strategy. Macroeconomic headwinds, government policy disruptions, and competitive pressures in the life science real estate market pose significant risks to future profitability and cash flows. While cost-cutting measures and strategic leasing are positive, they are currently overshadowed by the negative financial performance and challenging market conditions. The uncertainty surrounding future project development and asset dispositions further adds to the downside risk, making a 'sell' recommendation appropriate for a seasoned investor.

Keywords

REIT, life science, real estate, Megacampus, financial results, impairments, leasing, occupancy, capital markets, government policy, biotechnology, R&D, tariffs, debt, FFO, EPS, dispositions, development, corporate governance